Fig. 1From: Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST RegistryPatient selection. *Prednisolone equivalent dose. GC, glucocorticoid; D2T RA, difficult-to-treat rheumatoid arthritis; vD2T RA, very difficult-to-treat RA; b/tsDMARD, biologic and targeted synthetic disease-modifying anti-rheumatic drugsBack to article page